ELKTON — This time next year, it will be Brad Carillo’s turn in the hot seat for the Elkton Alliance Celebrity Roast. Elkton Commissioner Rob Massimiano, MC of the Saturday
Curaleaf Completes Acquisition of EMMAC and Secures US$130 Million Investment from a Single Strategic Institutional Investor
News provided by
Share this article
Share this article
EMMAC brings vertically integrated operations in Europe with a presence in key medical cannabis markets, including the UK, Germany, Italy, Spain, and Portugal
Strategic investor to fund cash portion of acquisition and Curaleaf s growth initiatives in Europe
WAKEFIELD, Mass., April 7, 2021 /PRNewswire/
Curaleaf Holdings, Inc. (CSE: CURA /OTCQX: CURLF) ( Curaleaf or the Company ), a leading international provider of consumer products in cannabis has successfully completed the previously announced acquisition of EMMAC Life Sciences Limited ( EMMAC ), the largest vertically integrated independent cannabis company in Europe, for base consideration of approximately US$50 million in cash and 17.5 million shares of Curaleaf, with additional consideration to be paid based upon the successful achievement
Curaleaf Completes Acquisition of EMMAC and Secures US$130 Million Investment from a Single Strategic Institutional Investor
Curaleaf Holdings, Inc. (CSE: CURA / OTCQX: CURLF) (âCuraleafâ or the âCompanyâ), a leading international provider of consumer products in cannabis has successfully completed the previously announced acquisition of EMMAC Life Sciences Limited (âEMMACâ), the largest vertically integrated independent cannabis company in Europe, for base consideration of approximately US$50 million in cash and 17.5 million shares of Curaleaf, with additional consideration to be paid based upon the successful achievement of performance milestones. Curaleaf has simultaneously established Curaleaf International Holdings Limited (âCuraleaf Internationalâ) in Guernsey to hold the EMMAC investment and further its European expansion.
Share this article
WAKEFIELD, Mass., March 9, 2021 /PRNewswire/
Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ( Curaleaf or the Company ), a leading U.S. provider of consumer products in cannabis, today announced that it has signed a definitive agreement to acquire EMMAC Life Sciences Limited ( EMMAC ), the largest vertically integrated independent cannabis company in Europe for base consideration of approximately US$286 million to be paid 85% in Curaleaf subordinate voting shares and 15% in cash. Contingent consideration of up to US$57 million will be paid in Curaleaf subordinate voting shares and cash in the same ratio based upon the successful achievement of performance milestones. The proposed transaction provides Curaleaf with a developed platform for entry into the European cannabis market.